{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Differentiation&page=4", "query": { "condition": "Differentiation", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 406, "total_pages": 41, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Differentiation&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Differentiation&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T12:43:21.462Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urothelial Carcinoma", "Renal Cell Carcinoma", "Non-Small Cell Lung Cancer", "Castration-resistant Prostate Cancer", "Triple Negative Breast Cancer", "Ovarian Cancer", "Endometrial Cancer", "Hepatocellular Carcinoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Colorectal Cancer", "Head and Neck Cancer", "Differentiated Thyroid Cancer", "Lower Esophageal Cancer" ], "interventions": [ { "name": "cabozantinib", "type": "DRUG" }, { "name": "atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 914, "start_date": "2017-09-05", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-25T12:43:21.462Z", "location_count": 57, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03170960" }, { "nct_id": "NCT00295763", "title": "A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Differentiated Thyroid Cancer" ], "interventions": [ { "name": "Thyrogen (thyrotropin alfa for injection)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2006-05", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2015-03-18", "last_synced_at": "2026-10-25T12:43:21.462Z", "location_count": 4, "location_summary": "Aurora, Colorado • Baltimore, Maryland • Columbus, Ohio + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00295763" }, { "nct_id": "NCT02345460", "title": "Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma", "Poorly Differentiated Malignant Neoplasm", "Resectable Pancreatic Cancer", "Stage IA Pancreatic Cancer", "Stage IB Pancreatic Cancer", "Stage IIA Pancreatic Cancer", "Stage IIB Pancreatic Cancer", "Stage III Pancreatic Cancer", "Undifferentiated Pancreatic Carcinoma" ], "interventions": [ { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1, "start_date": "2015-09", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2018-07-13", "last_synced_at": "2026-10-25T12:43:21.462Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02345460" }, { "nct_id": "NCT00002925", "title": "Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "ara-C", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "PSC-833", "type": "DRUG" }, { "name": "Aldesleukin", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "59 Years", "sex": "ALL", "summary": "15 Years to 59 Years" }, "enrollment_count": 410, "start_date": "1997-02", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2012-11-30", "last_synced_at": "2026-10-25T12:43:21.462Z", "location_count": 33, "location_summary": "La Jolla, California • San Francisco, California • Wilmington, Delaware + 24 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002925" }, { "nct_id": "NCT00095797", "title": "XK469R in Treating Patients With Refractory Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Basophilic Leukemia", "Adult Acute Eosinophilic Leukemia", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Blastic Phase Chronic Myelogenous Leukemia", "Chronic Myelomonocytic Leukemia", "de Novo Myelodysplastic Syndromes", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Excess Blasts in Transformation", "Refractory Chronic Lymphocytic Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Secondary Myelodysplastic Syndromes", "Stage III Chronic Lymphocytic Leukemia", "Stage IV Chronic Lymphocytic Leukemia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "R(+)XK469", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2004-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-08", "last_synced_at": "2026-10-25T12:43:21.462Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00095797" }, { "nct_id": "NCT02393690", "title": "Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Thyroid Gland Carcinoma", "Poorly Differentiated Thyroid Gland Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Stage IV Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IV Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7" ], "interventions": [ { "name": "Iodine I-131", "type": "RADIATION" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Selumetinib", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "OTHER", "DRUG" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2015-05-04", "completion_date": "2023-12-31", "has_results": true, "last_update_posted_date": "2024-07-26", "last_synced_at": "2026-10-25T12:43:21.462Z", "location_count": 11, "location_summary": "La Jolla, California • Newport Beach, California • Aurora, Colorado + 8 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02393690" }, { "nct_id": "NCT01342887", "title": "Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Recurrent Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "cyclosporine", "type": "DRUG" }, { "name": "pravastatin sodium", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "bone marrow aspiration", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2011-04", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-10-25T12:43:21.462Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01342887" }, { "nct_id": "NCT04035226", "title": "A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "No intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Janssen-Cilag Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 254, "start_date": "2019-08-02", "completion_date": "2022-10-27", "has_results": false, "last_update_posted_date": "2025-03-30", "last_synced_at": "2026-10-25T12:43:21.462Z", "location_count": 12, "location_summary": "Glendale, California • Greenbrae, California • Weeki Wachee, Florida + 9 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Weeki Wachee", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Southfield", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04035226" }, { "nct_id": "NCT06252493", "title": "Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Crohn Disease" ], "interventions": [ { "name": "Radiotracer Injection", "type": "DRUG" }, { "name": "Contrast Media, Magnetic Resonance", "type": "DRUG" }, { "name": "Blood Draw", "type": "DIAGNOSTIC_TEST" }, { "name": "Glucagon", "type": "DRUG" }, { "name": "Imaging", "type": "DIAGNOSTIC_TEST" }, { "name": "Oral contrast media application", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 25, "start_date": "2023-12-19", "completion_date": "2029-12-19", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-10-25T12:43:21.462Z", "location_count": 1, "location_summary": "Charlestown, Massachusetts", "locations": [ { "city": "Charlestown", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06252493" }, { "nct_id": "NCT06440850", "title": "Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thyroid Gland Follicular Carcinoma", "Thyroid Gland Oncocytic Carcinoma", "Thyroid Gland Papillary Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Diagnostic Imaging", "type": "PROCEDURE" }, { "name": "I-131 Uptake Test", "type": "PROCEDURE" }, { "name": "Iodine I-131", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Recombinant Thyrotropin Alfa", "type": "BIOLOGICAL" }, { "name": "Ultrasound Imaging", "type": "PROCEDURE" }, { "name": "Vemurafenib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2024-07-15", "completion_date": "2026-11-22", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-10-25T12:43:21.462Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06440850" } ] }